Full text is available at the source.
GLP-1 receptor agonists and clinical outcomes in patients with type 2 diabetes undergoing transcatheter aortic valve implantation
GLP-1 Medicines and Health Outcomes in Type 2 Diabetes Patients Having Heart Valve Replacement
AI simplified
Abstract
Use of GLP-1 receptor agonists (GLP1-RAs) after transcatheter aortic-valve implantation (TAVI) is associated with a higher survival probability and improved cardiorenal outcomes in patients with type 2 diabetes.
- GLP1-RA users demonstrated a survival probability increase (HR 0.708 [95% CI, 0.583-0.859]).
- There were lower rates of all-cause hospitalization for GLP1-RA users (HR 0.790 [95% CI, 0.706-0.885]).
- Major cardiovascular events occurred less frequently in GLP1-RA users (HR 0.849 [95% CI, 0.749-0.963]).
- Acute heart failure exacerbation rates were lower among those using GLP1-RAs (HR 0.785 [95% CI, 0.677-0.909]).
- GLP1-RA use was associated with a reduction in acute kidney injury (HR 0.843 [95% CI, 0.719-0.988]) and major kidney events (HR 0.665 [95% CI, 0.510-0.866]).
- No significant differences were found between groups for acute myocardial infarction, cerebral infarction, or cardiac arrest.
AI simplified